Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | HPGD | P15428 | 2/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | TUBB4A | P04350 | 6/20 | 0.54 |
| ▸ | TUBB | P07437 | 6/20 | 0.54 |
| ▸ | TUBA3C | P0DPH7 | 6/20 | 0.54 |
| ▸ | TUBA1B | P68363 | 6/20 | 0.54 |
| ▸ | TUBA4A | P68366 | 6/20 | 0.54 |
| ▸ | TUBB4B | P68371 | 6/20 | 0.54 |
| ▸ | TUBB3 | Q13509 | 6/20 | 0.54 |
| ▸ | TUBB2A | Q13885 | 6/20 | 0.54 |
| ▸ | TUBB8 | Q3ZCM7 | 6/20 | 0.54 |
| ▸ | TUBA3E | Q6PEY2 | 6/20 | 0.54 |
| ▸ | TUBA1A | Q71U36 | 6/20 | 0.54 |
| ▸ | TUBA1C | Q9BQE3 | 6/20 | 0.54 |
| ▸ | TUBB6 | Q9BUF5 | 6/20 | 0.54 |
| ▸ | TUBB2B | Q9BVA1 | 6/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL644752 | 0.79 | MEN1 (0.66) | MEN1KMT2AALDH1A1HPGDTP53 | |
| SCHEMBL27887288 | 0.79 | TP53 (0.79) | ALDH1A1GAATP53CHEK1RET | |
| SCHEMBL16539076 | 0.78 | TNFRSF1A (0.62) | MEN1KMT2AALDH1A1HPGDTUBB4A | |
| SCHEMBL16539079 | 0.78 | TNFRSF1A (0.62) | MEN1KMT2AALDH1A1HPGDTUBB4A | |
| SCHEMBL25196067 | 0.78 | ALPL (0.62) | MEN1KMT2AALDH1A1HPGDGAA | |
| Hydrochloric Acid SCHEMBL28800536 | 0.77 | TP53 (0.77) | ALDH1A1GAATP53CHEK1RET | |
| SCHEMBL30929863 | 0.76 | TUBB4A (0.56) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL15135543 | 0.76 | PDGFRB (0.59) | MEN1KMT2ATUBB4ATUBBTUBA3C | |
| SCHEMBL723265 | 0.75 | HSD17B14 (0.53) | MEN1KMT2ATUBB4ATUBBTUBA3C | |
| SCHEMBL25418742 | 0.75 | HDAC3 (0.62) | MEN1KMT2AALDH1A1HPGDGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250188072-A1 | COMPOUNDS FOR TREATMENT OF CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2025-06-12 | — | — | US | disclosed |
| US-12187720-B2 | Compounds for treatment of cancer | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2025-01-07 | — | — | US | disclosed |
| US-11465987-B2 | Compounds for treatment of cancer | Oncternal Therapeutics, Inc. (US) | 2022-10-11 | — | — | US | disclosed |
| US-20220024912-A1 | COMPOUNDS FOR TREATMENT OF CANCER | Oncternal Therapeutics, Inc. (US) | 2022-01-27 | — | — | US | disclosed |
| US-20220024912-A1 | COMPOUNDS FOR TREATMENT OF CANCER | Oncternal Therapeutics, Inc. (US) | 2022-01-27 | — | — | US | disclosed |
| US-11084811-B2 | Compounds for treatment of cancer | Oncternal Therapeutics, Inc. (US) | 2021-08-10 | — | — | US | disclosed |
| US-11084811-B2 | Compounds for treatment of cancer | Oncternal Therapeutics, Inc. (US) | 2021-08-10 | — | — | US | disclosed |
| EP-2608671-B1 | COMPOUNDS FOR TREATMENT OF CANCER | GTX INC (US) | 2018-12-12 | — | — | EP | disclosed |
| US-20170226086-A1 | COMPOUNDS FOR TREATMENT OF CANCER | GTx. Inc. (US) | 2017-08-10 | — | — | US | disclosed |
| US-20170226086-A1 | COMPOUNDS FOR TREATMENT OF CANCER | GTx. Inc. (US) | 2017-08-10 | — | — | US | disclosed |
| US-20120071524-A1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS, INC | 2012-03-22 | — | — | US | disclosed |
| US-20120071524-A1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS, INC | 2012-03-22 | — | — | US | disclosed |
| US-20120071524-A1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS, INC | 2012-03-22 | — | — | US | disclosed |
| WO-2012027481-A1 | COMPOUNDS FOR TREATMENT OF CANCER | GTX, INC. (US) | 2012-03-01 | — | — | WO | disclosed |
| WO-2012027481-A1 | COMPOUNDS FOR TREATMENT OF CANCER | GTX, INC. (US) | 2012-03-01 | — | — | WO | disclosed |
| US-20110257196-A1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS, INC | 2011-10-20 | — | — | US | disclosed |
| US-20110257196-A1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS, INC | 2011-10-20 | — | — | US | disclosed |
| US-20110257196-A1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS, INC | 2011-10-20 | — | — | US | disclosed |
| WO-2011109059-A1 | COMPOUNDS FOR TREATMENT OF CANCER | GTX, INC. (US) | 2011-09-09 | — | — | WO | disclosed |
| WO-2011109059-A1 | COMPOUNDS FOR TREATMENT OF CANCER | GTX, INC. (US) | 2011-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12187720-B2 | Compounds for treatment of cancer | KLK3, BRDT, ACP3 | MEN1 165/4885KMT2A 2242/4885ALDH1A1 209/4885 |
| US-20120071524-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | MEN1 165/4885KMT2A 2242/4885ALDH1A1 209/4885 |
| US-11084811-B2 | Compounds for treatment of cancer | KLK3, BRDT, ACP3 | MEN1 165/4885KMT2A 2242/4885ALDH1A1 209/4885 |
| US-20220024912-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | MEN1 165/4885KMT2A 2242/4885ALDH1A1 209/4885 |
| US-20170226086-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | MEN1 165/4885KMT2A 2242/4885ALDH1A1 209/4885 |
| US-20110257196-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | MEN1 165/4885KMT2A 2242/4885ALDH1A1 209/4885 |
| US-20250188072-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | MEN1 165/4885KMT2A 2242/4885ALDH1A1 209/4885 |
| US-11465987-B2 | Compounds for treatment of cancer | KLK3, BRDT, ACP3 | MEN1 165/4885KMT2A 2242/4885ALDH1A1 209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.